Reported Standalone quarterly numbers for Sun Pharma Advanced Research Company are:
Net Sales at Rs 13.86 crore in December 2023 down 89.43% from Rs. 131.09 crore in December 2022.
Story continues below Advertisement
Quarterly Net Loss at Rs. 99.65 crore in December 2023 down 1081.77% from Rs. 10.15 crore in December 2022.
EBITDA stands negative at Rs. 96.23 crore in December 2023 down 693.65% from Rs. 16.21 crore in December 2022.
Sun Pharma Adv shares closed at 371.10 on February 06, 2024 (NSE) and has given 58.42% returns over the last 6 months and 91.78% over the last 12 months.
Story continues below Advertisement
| Sun Pharma Advanced Research Company | | Standalone Quarterly Results | in Rs. Cr. |
|
| Dec'23 | Sep'23 | Dec'22 | | Net Sales/Income from operations | 13.86 | 21.18 | 131.09 | | Other Operating Income | -- | -- | -- | | Total Income From Operations | 13.86 | 21.18 | 131.09 | | EXPENDITURE | | Consumption of Raw Materials | 9.03 | 6.47 | 5.05 | | Purchase of Traded Goods | -- | -- | -- | | Increase/Decrease in Stocks | -- | -- | -- | | Power & Fuel | -- | -- | -- | | Employees Cost | 29.98 | 30.71 | 25.66 | | Depreciation | 3.16 | 3.18 | 3.13 | | Excise Duty | -- | -- | -- | | Admin. And Selling Expenses | -- | -- | -- | | R & D Expenses | -- | -- | -- | | Provisions And Contingencies | -- | -- | -- | | Exp. Capitalised | -- | -- | -- | | Other Expenses | 77.47 | 75.47 | 84.20 | | P/L Before Other Inc. , Int., Excpt. Items & Tax | -105.78 | -94.65 | 13.05 | | Other Income | 6.39 | 8.49 | 0.03 | | P/L Before Int., Excpt. Items & Tax | -99.39 | -86.16 | 13.08 | | Interest | 0.26 | 0.26 | 2.93 | | P/L Before Exceptional Items & Tax | -99.65 | -86.42 | 10.15 | | Exceptional Items | -- | -- | -- | | P/L Before Tax | -99.65 | -86.42 | 10.15 | | Tax | -- | -- | -- | | P/L After Tax from Ordinary Activities | -99.65 | -86.42 | 10.15 | | Prior Year Adjustments | -- | -- | -- | | Extra Ordinary Items | -- | -- | -- | | Net Profit/(Loss) For the Period | -99.65 | -86.42 | 10.15 | | Equity Share Capital | 32.45 | 32.45 | 27.53 | | Reserves Excluding Revaluation Reserves | -- | -- | -- | | Equity Dividend Rate (%) | -- | -- | -- | | EPS Before Extra Ordinary | | Basic EPS | -3.07 | -2.66 | 0.37 | | Diluted EPS | -3.07 | -2.66 | 0.35 | | EPS After Extra Ordinary | | Basic EPS | -3.07 | -2.66 | 0.37 | | Diluted EPS | -3.07 | -2.66 | 0.35 | | Public Share Holding | | No Of Shares (Crores) | -- | -- | -- | | Share Holding (%) | -- | -- | -- | | Promoters and Promoter Group Shareholding | | a) Pledged/Encumbered | | - Number of shares (Crores) | -- | -- | -- | | - Per. of shares (as a % of the total sh. of prom. and promoter group) | -- | -- | -- | | - Per. of shares (as a % of the total Share Cap. of the company) | -- | -- | -- | | b) Non-encumbered | | - Number of shares (Crores) | -- | -- | -- | | - Per. of shares (as a % of the total sh. of prom. and promoter group) | -- | -- | -- | | - Per. of shares (as a % of the total Share Cap. of the company) | -- | -- | -- | | Source : Dion Global Solutions Limited |
|
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
